AcelRx Pharmaceuticals, Inc. (ACRX)
(Delayed Data from NSDQ)
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Top Ranked Momentum Stocks to Buy for June 7th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, June 7th:
Top Ranked Momentum Stocks to Buy for June 5th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, June 5th:
Top Ranked Momentum Stocks to Buy for June 4th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 4th:
Top Ranked Momentum Stocks to Buy for May 18th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 18th:
Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
by Zacks Equity Research
Surging implied volatility makes AcelRx Pharmaceuticals (ACRX) lucrative to the option traders.
Omeros Inks Agreement With FDA for OMS721 Phase III Trial
by Zacks Equity Research
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Merck's Keytruda Gets Approved for Bladder Cancer in Japan
by Zacks Equity Research
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.
5 Reasons to Pick Emergent as an Investment-Worthy Stock
by Zacks Equity Research
Other than a bullish rank, there are several factors that make Emergent (EBS) a solid investment in 2018.
Actinium Posts Positive DMC View on Lomab-B Phase III Trial
by Zacks Equity Research
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
AcelRx's Opioid Painkiller Dsuvia Gets CRL, Shares Plunge
by Zacks Equity Research
AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Moves 19.6% Higher
by Zacks Equity Research
AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.
3 Biotech and Pharma Stocks with Key FDA Catalysts this October
by Arpita Dutt
Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.
Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3%
by Zacks Equity Research
AcelRx Pharmaceuticals, Inc.(ACRX) was a big mover last session, as the company saw its shares rise over 5% on the day.